Your browser is no longer supported. Please, upgrade your browser.
Settings
ZYME Zymeworks Inc. daily Stock Chart
ZYME [NYSE]
Zymeworks Inc.
Index- P/E- EPS (ttm)-2.27 Insider Own46.08% Shs Outstand25.46M Perf Week8.28%
Market Cap261.62M Forward P/E- EPS next Y-2.29 Insider Trans- Shs Float13.71M Perf Month38.67%
Income-54.40M PEG- EPS next Q-0.01 Inst Own13.60% Short Float0.34% Perf Quarter14.05%
Sales3.90M P/S67.08 EPS this Y-76.40% Inst Trans10.53% Short Ratio2.27 Perf Half Y28.93%
Book/sh3.26 P/B3.15 EPS next Y23.90% ROA-56.10% Target Price16.00 Perf Year-
Cash/sh1.93 P/C5.33 EPS next 5Y- ROE-121.20% 52W Range6.25 - 14.25 Perf YTD35.33%
Dividend- P/FCF- EPS past 5Y- ROI-244.70% 52W High-27.89% Beta-
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low64.41% ATR0.40
Employees136 Current Ratio4.60 Sales Q/Q-95.50% Oper. Margin- RSI (14)75.65 Volatility5.06% 4.23%
OptionableNo Debt/Eq0.00 EPS Q/Q32.10% Profit Margin- Rel Volume0.39 Prev Close9.95
ShortableYes LT Debt/Eq0.00 EarningsFeb 07 AMC Payout- Avg Volume20.69K Price10.28
Recom1.80 SMA2022.54% SMA5025.47% SMA20016.19% Volume7,998 Change3.27%
Jan-07-18 07:00PM  Zymeworks Highlights Key 2017 Accomplishments and Announces 2018 Priorities Business Wire
Dec-28-17 03:29PM  Lifshitz & Miller LLP Announces Investigation of Alon USA Partners, LP, Amplify Snack Brands, Inc., Kindred Healthcare, Inc., Pinnacle Entertainment, Inc., Regal Entertainment Group, Sigma Designs, Inc. and Zymeworks Inc. PR Newswire
Dec-20-17 10:03PM  ZYME INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Zymeworks Inc. Investors Business Wire
Dec-15-17 06:46AM  Zymeworks (ZYME) Alert: Johnson Fistel Announces Investigation of Zymeworks Inc.; Encourages Investors to Contact the Firm for Additional Information PR Newswire -6.27%
Dec-05-17 05:00AM  Zymeworks Presents Results of the Completed Dose Escalation Portion of the Ongoing Phase 1 Study of ZW25 at the San Antonio Breast Cancer Symposium Business Wire +6.86%
Nov-15-17 07:30AM  Featured Company News - Zymeworks Enters Into License Agreement with Janssen Biotech to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics ACCESSWIRE
Nov-13-17 04:15PM  Zymeworks to Present at Upcoming 2017 Stifel Healthcare Conference Business Wire +24.75%
05:00AM  Zymeworks Announces License Agreement with Johnson & Johnson Innovation to Develop and Commercialize Next Generation Bispecific Antibody Therapeutics Business Wire
Nov-08-17 04:15PM  Zymeworks Reports Third Quarter 2017 Financial Results and Provides Business Update Business Wire
Sep-19-17 05:00AM  Merck to Advance Bispecific Antibody Drug Candidate Developed Using Zymeworks Azymetric Platform into Preclinical Development Business Wire
Sep-11-17 07:15AM  Zymeworks Presents Additional Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the European Society for Medical Oncology 2017 Congress (ESMO) Business Wire
Sep-07-17 01:59PM  2 Names Barclays Is Now Bearish On In Biotech Benzinga -6.89%
Sep-06-17 05:00AM  Zymeworks to Present at the European Society for Medical Oncology 2017 Congress and Hold Webcast to Review Clinical Results Business Wire
Aug-29-17 05:00AM  Zymeworks to Participate in Upcoming Healthcare and Biotech Conferences Business Wire +7.71%
Aug-08-17 04:01PM  Zymeworks Reports Second Quarter 2017 Financial Results Business Wire
Aug-04-17 04:05PM  Zymeworks to Present at 37th Annual Canaccord Genuity Growth Conference Business Wire
Aug-03-17 05:00AM  Zymeworks Appoints Dr. Natalie Sacks to its Board of Directors Business Wire
Aug-01-17 04:30PM  Zymeworks to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017 Business Wire
Jul-18-17 05:00AM  Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration Business Wire
Jun-12-17 07:00AM  Drug Candidates Developed Using Zymeworks Azymetric Platform Nominated for Late-Stage, Preclinical Development by Lilly Business Wire
Jun-04-17 09:00AM  Zymeworks Presents Safety and Anti-Tumor Activity Data from the Ongoing Phase 1 Study of ZW25 at the American Society of Clinical Oncology Annual Meeting (ASCO 2017) Business Wire
May-26-17 07:59AM  Zymeworks Announces Partial Exercise of Over-Allotment Option for its Initial Public Offering Business Wire
May-23-17 02:09PM  Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst Benzinga
May-17-17 05:00PM  Zymeworks to Present at the 2017 American Society of Clinical Oncology Annual Meeting Business Wire
May-15-17 04:01PM  Zymeworks Reports First Quarter 2017 Financial Results Business Wire
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate include ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast, gastric, and ovarian cancers. It is also developing ZW33, a bispecific anti-human epidermal growth factor receptor 2 antibody-drug conjugate that is in preclinical development stage for the treatment of breast and ovarian cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Celgene Corporation and Celgene Alpine Investment Co. LLC, GlaxoSmithKline Intellectual Property Development Limited, and Daiichi Sankyo Co., Ltd. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.